I think practices in many areas are waiting for the payment risk to pass. After Jan 1 there will be a dedicated J code to bill for getting paid in a timely manner. It can take up to 5 months to get paid and at $8800 that can affect cash flow.
Looks even better now. I thought my stock was going to get called out last expiration at the $5 strike, glad it didn't. Hoping for a PR for a big catalyst, otherwise waiting for ER in Aug.
Sentiment: Strong Buy
Yes and yes. That's why to me they should be able to show us at least 400 units a month this quarter. 1/3 of that could come from Europe that leaves only 250 or so units a month in the US. If they can't do something near that I'm not sure how they will convince the institutional world to invest in the company. What large investors want to know is that alim has a clear path to profitability and no further need to raise cash. Absent that you will see continued lack of support like we are seeing now.
Wont the reimbursement issues be completely resolved by Jan 1, 2016? Hasn't there been favorable response from the insurance companies?
Sentiment: Strong Buy
It shouldn't be a problem for a small co like alim to ramp up in this market because there are only 1000 retina centers they are focused on and they have 32 reps to cover them. It's not like they are calling on general practitioners and need 300-400 reps. The bigger issue is the perception by the docs as to whether or not it is an appropriate therapy for some portion of their patient base.
What would change the trajectory of stock price would be a quarter of sales that indicates progress on physician acceptance.
Currently the stock is trading 20 - 30 percent lower than before the FDA approval last fall. And in a market which otherwise only have known one direction since then - and this is up and especially in the overall biotek marked.
I believe that the general view in the market is that there currently are better places to put your money and therefore the PPS is going down, slowly but surely.
To ramp up a new product in a large market is almost always a big - or too large - mouthful for a small company like Alimera. And the slow ramp up in Europe reduce the interest even more. My hope was - and to a certain point still is - that Alimere after the US approval would be bought up - but unfortunately this did not occur, and now trading intetrest in might be even lower than the activity of this MB :-)
I just have to admit that my investments in ALimera and Psivida so far been miserable - no matter if I look in the short or long term. However, there is still the dreams - but they are of no value in itself.
I also bought below 4§ dollars yesterday - but, at the moment it feels like throwing good money after bad money. Most likely they will be even cheaper in the days to come - we are in a severe down trend and on the short term it is hard to point out what will changes this.
I think their sales were weak for Q1 and their data on a significant improvement for this quarter were weak as well. In addition institutions that have participated in the conferences they've held are not buying the story.
Dan's optimism is great but they need to show that the docs are actually going to adopt this and that ALIM is not another money losing, 20 million in sales, little niche pharma.
Personally I'd like to see 10 mil in sales this quarter at a minimum. That's only 1200 or so units or 400 a month. Of the 1000 retina centers they are in contact with you could assume 60% of them do nothing and you would only need to sell one unit a month to the other 400 to hit 10 mil in sales.
It's now been almost 9 months since approval and they have a more open label than they expected. Time for Dan to deliver on years of promises!
Those were my thoughts. I figured it was the best time to buy since it was at its 52wk low. I got in at $3.98. My dd makes me believe that this stock will see brighter days later this year.
I think......I should have picked some of those up on 350K volume.
Hard to believe, with Iluvien picking up a bit of steam in the DME market, shares
would be that low. Any thoughts?
As long as things continue on the path of the last couple of months I think the stock will do fine. Needs to be watched but right now things are going as expected. The acceptance by doctors shown in the slides is good but needs to grow and I think it will. The number of insurance requests being processed needs to continue growing each month.
I see. I have been to these type of conferences and surprised at this. Usually when this changes, the company has decided it, not the conference folks. Do you think this stock has been manipulated? I think this is just the beginning for them in positive way. They have been approved in many countries and have begun marketing in the US. But yet it trades like a dog.